{"id":"brimonidine-tartrate-0-025","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular hyperemia (redness)"},{"rate":null,"effect":"Ocular allergic reactions"},{"rate":null,"effect":"Dry eye"},{"rate":null,"effect":"Follicular conjunctivitis"},{"rate":null,"effect":"Systemic hypotension"}]},"_chembl":{"chemblId":"CHEMBL1200389","moleculeType":"Small molecule","molecularWeight":"442.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brimonidine selectively binds to alpha-2 adrenergic receptors on the ciliary body and trabecular meshwork of the eye. This activation reduces aqueous humor synthesis and enhances drainage through the uveoscleral pathway, thereby lowering intraocular pressure. The 0.025% concentration represents a lower-dose formulation designed to minimize systemic absorption and associated side effects.","oneSentence":"Brimonidine tartrate is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:05.551Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma or ocular hypertension (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07390578","phase":"PHASE4","title":"Upneeq vs. Lumify Ptosis","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-03-01","conditions":"Acquired Ptosis","enrollment":50},{"nctId":"NCT07209410","phase":"PHASE4","title":"Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma","status":"RECRUITING","sponsor":"Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,","startDate":"2025-11-01","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT04007276","phase":"PHASE4","title":"The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Tulane University","startDate":"2026-11-10","conditions":"Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs","enrollment":60},{"nctId":"NCT05815758","phase":"PHASE3","title":"Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2023-04-20","conditions":"Allergic Conjunctivitis","enrollment":512},{"nctId":"NCT06803654","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-05-22","conditions":"Ocular Redness","enrollment":578},{"nctId":"NCT05591755","phase":"PHASE3","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-11-18","conditions":"Seasonal Allergic Conjunctivitis","enrollment":229},{"nctId":"NCT06996236","phase":"PHASE2","title":"Brimonidine Eye Drops in the Prevention of Myopia Progression","status":"NOT_YET_RECRUITING","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2025-07","conditions":"Myopia","enrollment":40},{"nctId":"NCT05579730","phase":"PHASE3","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-10-12","conditions":"Allergic Conjunctivitis","enrollment":188},{"nctId":"NCT05360784","phase":"PHASE3","title":"\"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness\"","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-05-13","conditions":"Ocular Redness","enrollment":380},{"nctId":"NCT03782701","phase":"PHASE4","title":"The Effect of Lumify™ Eyedrops on Eyelid Position","status":"COMPLETED","sponsor":"University of Miami","startDate":"2019-06-18","conditions":"Eyelid Droop","enrollment":43},{"nctId":"NCT04683159","phase":"NA","title":"Brimonidine Tartrate for Pterygium Surgery","status":"UNKNOWN","sponsor":"Uptown Eye Specialists","startDate":"2021-02","conditions":"Pterygium, Subconjunctival Hemorrhage","enrollment":66},{"nctId":"NCT01959243","phase":"PHASE3","title":"Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2014-02-22","conditions":"Hyperemia","enrollment":507},{"nctId":"NCT01959230","phase":"PHASE3","title":"Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-11-07","conditions":"Hyperemia","enrollment":60},{"nctId":"NCT02039765","phase":"PHASE1","title":"Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2014-02","conditions":"Hyperemia","enrollment":12},{"nctId":"NCT01675609","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects","status":"COMPLETED","sponsor":"Eye Therapies, LLC","startDate":"2012-08","conditions":"Ocular Redness","enrollment":57},{"nctId":"NCT01687426","phase":"PHASE1","title":"Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Eye Therapies, LLC","startDate":"2012-09","conditions":"Glaucoma and Ocular Hypertension","enrollment":15},{"nctId":"NCT01275105","phase":"PHASE2","title":"A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)","status":"COMPLETED","sponsor":"Eye Therapies, LLC","startDate":"2011-01","conditions":"Allergic Conjunctivitis","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Brimonidine Tartrate 0.025%","genericName":"Brimonidine Tartrate 0.025%","companyName":"Eye Therapies, LLC","companyId":"eye-therapies-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brimonidine tartrate is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Used for Glaucoma or ocular hypertension (Phase 3 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}